Skip to main content
OpenTrials
Completed

NCT Number: NCT05596006

Efficacy of ASIMOMMY® Compared to Domperidone and Placebo in Increasing Breastfeeding: Randomized Single-Blind Controlled Trial in Indonesia

The purpose of this study is assess the efficacy of ASIMOMMY® in increasing breast milk production in postpartum mothers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–35 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Primary Health Center Jetis and Tegalrejo

Yogyakarta, DI Yogyakarta, 55242, Indonesia

About this study

Several traditional herbs have been used and is well known since a long time ago by Indonesian people to increase the production of breastmilk, such as Katuk leaves (Sauropus androgynous Folium), Fenugreek (Trigonella foenum-graceum), and Moringa leaves (Moringa oleifera Folium). These plants have been scientifically proven through preclinical and even clinical research. However, not many have been further developed as phytopharmaceuticals that can be used in formal health services.

In previous research, ASI MOMMY® capsules have been successfully produced in accordance to the traditional method of making good herbal drugs, with each capsule containing extracts of Katuk leaf (300 mg), Fenugreek (150 mg), and Moringa leaf (50 mg). This formulation has gone through pharmacodynamic activity test, and acute and subactute toxicity test. Research has shown that ASI MOMMY® is works actively as a galactogogue and is not toxic, therefore it is safe to be given to humans (unpublished),

No research has been done to test the benefits of ASI MOMMY® in increasinng breastmilk production. Therefore, this research is a clinical trial that intends to see the benefits of ASI MOMMY® for increasing breastmilk production in postpartum women. This research is a part of the previous main research that is still ongoing to this day which aims to develop the formulation of ASI MOMMY® as a phytopharmaceutical

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Mothers 20-35 years old.
  • Gestational age at delivery 37-40 weeks.
  • Vaginal delivery.
  • Normal body mass index (BMI 18.5-24.9 kg/m2).
  • Not taking drugs or breast milk enhancement supplements.
  • Healthy mother's condition with normal nipples (protruding).
  • Healthy baby condition with good suction reflex.
  • The baby consumes only breast milk.

Exclusion criteria

  • Allergy to ASI MOMMY® and Domperidon.
  • The mother is taking medications that affect the effects of domperidone (such as antacids, cimetidine, ranitidine, famotidine and nizatidine) or medications that interact with domperidone (such as haloperidol, lithium).
  • The mother is in a state of illness requiring hospitalization.
  • Mother has HIV AIDS, heart problems, mastitis, and had undergone breast surgery.
  • Underweight, overweight and obese mothers.
  • Giving birth to twins.
  • The baby has a congenital defect that affects the suctioning process of breast milk
  • Infants and mothers who did not participate in the treatment until completion (day 7 of the intervention).

Treatment and study plan

ASIMOMMY®

Drug

ASIMOMMY 500 mg

Domperidon

Drug

Domperidone capsule 10 mg

Placebo

Drug

Capsules of placebo 500mg.

Primary outcomes

  1. Increase in Neonates Weight

    Time frame: Day 0 to day 7

    The primary outcome is the difference in the neonates weight after 7 days of treatment with ASIMOMMY® compared to mothers receiving domperidone and placebo (mean day 7 neonates weight minus mean day 0 neonates weight).

Secondary outcomes

  1. Proportion of non serious adverse event within 7 days

    Time frame: Day 0 to day 7

    Number of mothers or neonates who had non serious adverse event from day 0 to day 7 with ASIMOMMY® compare to mother receiving Domperidone and Placebo

  2. Proportion of serious adverse event within 7 days

    Time frame: Day 0 to day 7

    Number of mothers or neonates who had serious adverse event from day 0 to day 7 with ASIMOMMY® compare to mother receiving Domperidone and Placebo

Sponsors and collaborators

Lead sponsor

Gadjah Mada University

Other

Registry information

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Oct 27, 2022
Registry last updated
Mar 29, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.